这些植入物可能增加眼压(intraocular pressure,IOP)上升的风险(RR=2.81,95% CI [1.42, 5.56];2项试验,282名受试者;中等质量证据)和降眼压滴眼液的需求(RR=1.85,95% CI [1.05, 3.25];2项试验,282名受试者;中等质量证据),但不增加降眼压手术的需求(RR=0.72 ...
- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma ...